Holen Sie sich die Stockscreener-App
5.78
1.40%
0.08
Handel nachbörslich:
5.75
-0.03
-0.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$5.70
Offen:
$5.75
24-Stunden-Volumen:
1.72M
Relative Volume:
0.67
Marktkapitalisierung:
$446.68M
Einnahmen:
$409.00K
Nettoeinkommen (Verlust:
$-101.35M
KGV:
-3.5244
EPS:
-1.64
Netto-Cashflow:
$-71.49M
1W Leistung:
-0.34%
1M Leistung:
+27.59%
6M Leistung:
-24.05%
1J Leistung:
-34.84%
1-Tages-Spanne:
$5.60
$5.85
1-Wochen-Bereich:
$5.49
$6.13
52-Wochen-Spanne:
$3.553
$11.16
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Vergleichen Sie ALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
5.78 | 446.68M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.38 | 110.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.99 | 59.13B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
561.75 | 34.75B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.40 | 33.69B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
225.77 | 25.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada
Altimmune, Inc. SEC 10-Q Report - TradingView
Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha
ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia
Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Repor - GuruFocus
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Altimmune (ALT) Secures $100 Million Credit Facility to Advance Pemvidutide Development | ALT Stock News - GuruFocus
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital - marketscreener.com
Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus
Altimmune (ALT) Anticipates Q1 Earnings with Positive EPS Revisi - GuruFocus
Altimmune secures $100 million credit facility for drug development By Investing.com - Investing.com India
Altimmune Announces First Quarter 2025 Financial Results and Business Update - The Manila Times
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - The Manila Times
What to Expect from Altimmune's Earnings - Nasdaq
Stifel maintains Buy on Altimmune stock with $18 target By Investing.com - Investing.com UK
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune's (ALT) Pemvidutide Shows Promising Results in Liver H - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ | ALT Stock News - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - The Manila Times
Altimmune Presents Promising Analyses of Pemvidutide's Efficacy in MASH Treatment at EASL 2025 - Nasdaq
Altimmune at The Citizens JMP Life Sciences Conference: Pembidutide’s Promise - Investing.com
Altimmune to Report First Quarter 2025 Financial Results and Pro - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 | ALT Stock News - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - The Manila Times
Altimmune, Inc. to Announce Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Clinical-Stage Biotech Altimmune Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Trend Tracker for (ALT) - news.stocktradersdaily.com
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
What's Going On With Altimmune (ALT) Stock Today? - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - The Manila Times
Altimmune, Inc. to Showcase Novel MASH Resolution Index Data for Pemvidutide at EASL International Liver Congress™ 2025 - Nasdaq
Altimmune to Participate in the Citizens Life Sciences Conferenc - GuruFocus
Altimmune to Participate in the Citizens Life Sciences Conference - The Manila Times
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):